Cell and Gene Outsourcing

  1. How In-House CDMO Analytics Reduce Risk and Cost 10/21/2025

    Integrated analytical capabilities within a CDMO are increasingly preferred to overcome challenges associated with outsourcing analysis in biopharma development and manufacturing.

  2. The 9 Fastest-Growing Outsourcing Segments 10/21/2025

    Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

  3. Collaboration An Untapped Fuel For Driving Biopharma R&D 10/20/2025

    Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.

  4. Partnering To Advance Therapeutic Innovation: Clinical Trial Solutions 10/20/2025

    A global network supports clinical trials with integrated services including bioanalysis, central laboratory safety testing, pathology, and clinical supplies. Solutions cover every phase of drug development.

  5. How Global Supply Chain Centers Amplify CGT Program Growth 10/20/2025

    Consolidating logistics, cryopreservation, and storage eliminates handoffs and risk. This single-platform approach creates the consistency needed for global compliance and growth.

  6. Hidden Risks In Your Supply Chain: Regulatory Support Can Save Your CGT 10/20/2025

    Unvalidated shipping lanes and incomplete documentation can cause regulatory delays. Proactive qualification and risk assessments are vital for compliance and safeguarding product integrity.

  7. What's Next For ATMP Regulation In EMEA 10/20/2025

    Fragmented national regulations for pricing, customs, and reimbursement demand tailored supply chain strategies. Adapting to country-specific hurdles is essential for product integrity and patient access.

  8. The Future Of Lentiviral Vector Innovation And Access 10/17/2025

    Founded on lentiviral vector design and manufacturing excellence, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to quickly deliver state-of-the-art therapies and develop next-generation products.

  9. Power Your Gene Therapy Pipeline With A Proven AAV CDMO Partner 10/17/2025

    With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true end-to-end support, accelerating your path to the clinic and beyond.

  10. Why Asia Should Be Your Next Trial Destination 10/17/2025

    Many U.S. oncology sponsors are expanding their late-phase trials into Asia to secure access to rich patient pools, leverage efficient regulatory pathways, and save time and money in the clinic.